References
Huisman JF, Schoenaker IJH, Brohet RM, et al. Avoiding unnecessary major rectal cancer surgery by implementing structural restaging and a watch-and-wait strategy after neoadjuvant radiochemotherapy. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09192-0.
Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396. https://doi.org/10.1200/jco.1999.17.8.2396.
Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–42. https://doi.org/10.1093/annonc/mdw062.
Chakrabarti D, Rajan S, Akhtar N, et al. Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: a randomized clinical trial. Br J Surg. 2021. https://doi.org/10.1093/bjs/znab020.
Chakrabarti D, Rajan S, Akhtar N, Qayoom S, Verma M, Gupta R. Dose escalated short-course radiotherapy in rectal cancers: is this the way forward? Ann Oncol. 2020;31:S93–S94. https://doi.org/10.1016/j.annonc.2020.04.096.
Erlandsson J, Lörinc E, Ahlberg M, et al. Tumour regression after radiotherapy for rectal cancer: results from the randomised Stockholm III trial. Radiother Oncol. 2019;135:178–186. https://doi.org/10.1016/j.radonc.2019.03.016.
Ciseł B, Pietrzak L, Michalski W, et al. Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–1303. https://doi.org/10.1093/annonc/mdz186.
Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;22(1):29–42. https://doi.org/10.1016/S1470-2045(20)30555-6.
Conroy T, Lamfichekh N, Etienne P-L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2020;38(15 Suppl):4007. https://doi.org/10.1200/jco.2020.38.15_suppl.4007.
Goodman KA. Total neoadjuvant therapy for rectal cancer. Cancer Radiother. 2018;22(5):459–465. https://doi.org/10.1016/j.canrad.2018.01.004.
Healey Bird BRJ. Total neoadjuvant therapy for locally advanced rectal cancer: the fuse is lit. Br J Surg. 2020;107(13):1705–707. https://doi.org/10.1002/bjs.12014.
Funding
The authors have no funding to declare.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Deep Chakrabarti, Naseem Akhtar, Shiv Rajan, Sumaira Qayoom, Vijay Kumar, Arun Chaturvedi, Rajeev Gupta, and Madan Lal Brahma Bhatt have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chakrabarti, D., Akhtar, N., Rajan, S. et al. Intensifying Neoadjuvant Therapy for Rectal Cancers Towards Watchful Waiting. Ann Surg Oncol 28, 4062–4063 (2021). https://doi.org/10.1245/s10434-020-09512-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09512-4